dipyridamole has been researched along with Vascular Diseases in 45 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| " Conditions characterized by a reduction in platelet survival and where dipyridamole has been used include heart valve replacement, arterial grafting, cerebrovascular disorders, and disorders of peripheral circulation." | 6.15 | Dipyridamole: a critical evaluation. ( Alexander, MR; Rivey, MP; Taylor, JW, 1984) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| "The purpose of this study was to conduct a metaanalysis of semiquantitive dipyridamole myocardial perfusion scintigraphy for the prediction of perioperative myocardial infarction and cardiac death in patients undergoing noncardiac vascular surgery." | 4.81 | Semiquantitative dipyridamole myocardial stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a meta-analysis. ( Cook, D; Etchells, E; Meade, M; Tomlinson, G, 2002) |
| " The current study was performed to examine whether sex-specific differences exist in these outcomes in a large population of vascular surgery patients and to determine the value of clinical and dipyridamole thallium variables in predicting myocardial infarction and cardiac death." | 3.69 | Sex differences in perioperative and long-term cardiac event-free survival in vascular surgery patients. An analysis of clinical and scintigraphic variables. ( Chen, MH; Eagle, KA; Hendel, RC; L'Italien, GJ; Leppo, JA; Newell, JB; Paul, SD, 1995) |
| "We evaluated the usefulness of dipyridamole-thallium imaging for the detection of ischaemic heart disease in 257 patients with atherosclerotic vascular disease (80 patients with arteriosclerosis obliterans, 81 patients with aneurysm of the abdominal aorta, 60 patients with aneurysm of the thoracic aorta and 36 patients with dissecting aortic aneurysm)." | 3.69 | Usefulness of dipyridamole-thallium imaging in 257 patients with atherosclerotic vascular disease. ( Hayashida, K; Ishida, Y; Nishimura, T; Shimonagata, T; Toyama, T; Uehara, T, 1995) |
| " The transient dyssynergy detected by two-dimensional echocardiography and evoked during dipyridamole infusion is a marker of coronary disease that is equally reliable in normotensive and hypertensive individuals." | 3.68 | Dipyridamole echocardiography stress testing in hypertensive patients. Targets and tools. ( Camici, P; L'Abbate, A; Lattanzi, F; Lucarini, AR; Marini, C; Picano, E; Salvetti, A, 1991) |
| "Dipyridamole was not more efficacious in the prevention of vascular death (relative risk [RR], 1." | 2.42 | Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. ( Algra, A; De Schryver, EL; van Gijn, J, 2003) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (42.22) | 18.7374 |
| 1990's | 13 (28.89) | 18.2507 |
| 2000's | 10 (22.22) | 29.6817 |
| 2010's | 3 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sacco, RL | 1 |
| Diener, HC | 2 |
| Yusuf, S | 2 |
| Cotton, D | 2 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 1 |
| Martin, RH | 2 |
| Albers, GW | 1 |
| Bath, P | 1 |
| Bornstein, N | 1 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Cunha, L | 1 |
| Dahlöf, B | 1 |
| De Keyser, J | 1 |
| Donnan, GA | 2 |
| Estol, C | 1 |
| Gorelick, P | 1 |
| Gu, V | 1 |
| Hermansson, K | 1 |
| Hilbrich, L | 1 |
| Kaste, M | 1 |
| Lu, C | 1 |
| Machnig, T | 1 |
| Pais, P | 1 |
| Roberts, R | 1 |
| Skvortsova, V | 1 |
| Teal, P | 1 |
| Toni, D | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Yoon, BW | 1 |
| Agirbasli, M | 1 |
| Eren, M | 1 |
| Eren, F | 1 |
| Murphy, SB | 1 |
| Serdar, ZA | 1 |
| Seckin, D | 1 |
| Zara, T | 1 |
| Cem Mat, M | 1 |
| Demirkesen, C | 1 |
| Vaughan, DE | 1 |
| Stewart, K | 1 |
| Walters, M | 1 |
| Dawson, J | 1 |
| Ovbiagele, B | 1 |
| Vinisko, R | 1 |
| Bath, PM | 1 |
| Etchells, E | 1 |
| Meade, M | 1 |
| Tomlinson, G | 1 |
| Cook, D | 1 |
| De Schryver, EL | 4 |
| Algra, A | 4 |
| van Gijn, J | 4 |
| Kertai, MD | 1 |
| Boersma, E | 1 |
| Bax, JJ | 1 |
| Heijenbrok-Kal, MH | 1 |
| Hunink, MG | 1 |
| L'talien, GJ | 1 |
| Roelandt, JR | 1 |
| van Urk, H | 1 |
| Poldermans, D | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Hughes, DA | 1 |
| Mehta, AB | 1 |
| Einhäupl, K | 1 |
| Webster, J | 1 |
| Rivey, MP | 1 |
| Alexander, MR | 1 |
| Taylor, JW | 1 |
| Strobl-Jäger, E | 1 |
| Kaliman, J | 1 |
| Sinzinger, H | 1 |
| Silver, MJ | 1 |
| Ingerman-Wojenski, CM | 1 |
| Sedar, AW | 1 |
| Smith, M | 1 |
| Morris-Jones, W | 1 |
| Preston, FE | 1 |
| Chen, WY | 1 |
| Lee, FN | 1 |
| Hsieh, BS | 1 |
| Yen, TS | 1 |
| Chou, JH | 1 |
| Poliwoda, H | 1 |
| Redonnet, M | 1 |
| Derumeaux, G | 1 |
| Mouton-Schleifer, D | 1 |
| Litzler, PY | 1 |
| Segond, G | 1 |
| Bouchart, F | 1 |
| Bessou, JP | 1 |
| Letac, B | 1 |
| Soyer, R | 1 |
| Hendel, RC | 3 |
| Chen, MH | 1 |
| L'Italien, GJ | 2 |
| Newell, JB | 1 |
| Paul, SD | 2 |
| Eagle, KA | 3 |
| Leppo, JA | 3 |
| Green, D | 1 |
| Miller, V | 1 |
| McPhail, NV | 1 |
| Ruddy, TD | 1 |
| Barber, GG | 1 |
| Cole, CW | 1 |
| Marois, LJ | 1 |
| Gulenchyn, KY | 1 |
| Toyama, T | 1 |
| Uehara, T | 1 |
| Shimonagata, T | 1 |
| Hayashida, K | 1 |
| Ishida, Y | 1 |
| Nishimura, T | 1 |
| Cohen, MC | 1 |
| Fleisher, LA | 1 |
| Brown, KA | 1 |
| Zarich, SW | 1 |
| Cambria, RP | 1 |
| Cutler, BS | 3 |
| Goldman, L | 1 |
| Shaw, LJ | 1 |
| Gersh, BJ | 1 |
| Miller, DD | 1 |
| Klonaris, CN | 1 |
| Bastounis, EA | 1 |
| Xiromeritis, NC | 1 |
| Balas, PE | 1 |
| Itani, KM | 1 |
| Miller, CC | 1 |
| Guinn, G | 1 |
| Jones, JW | 1 |
| McGiff, JC | 1 |
| Harker, LA | 3 |
| Hirsh, J | 1 |
| Gent, M | 1 |
| Genton, E | 1 |
| Maher, JF | 1 |
| Hirszel, P | 1 |
| Abraham, JE | 1 |
| Galen, MA | 1 |
| Chamberlin, M | 1 |
| Hohnadel, DC | 1 |
| Lucarini, AR | 1 |
| Picano, E | 1 |
| Lattanzi, F | 1 |
| Camici, P | 1 |
| Marini, C | 1 |
| Salvetti, A | 1 |
| L'Abbate, A | 1 |
| Younis, LT | 1 |
| Aguirre, F | 1 |
| Byers, S | 1 |
| Dowell, S | 1 |
| Barth, G | 1 |
| Walker, H | 1 |
| Carrachi, B | 1 |
| Peterson, G | 1 |
| Chaitman, BR | 1 |
| Belcaro, G | 1 |
| Errichi, BM | 1 |
| Laurora, G | 1 |
| Marinucci, R | 1 |
| Cesarone, MR | 1 |
| De Cenzo, A | 1 |
| Strano, A | 1 |
| Davì, G | 1 |
| Cannizzaro, S | 1 |
| Giubilato, A | 1 |
| Kahn, DR | 1 |
| Dufek, JH | 1 |
| Oberman, HA | 1 |
| Beck, ML | 1 |
| Bree, M | 1 |
| Kirsh, MM | 1 |
| Moores, WY | 1 |
| Prior, M | 1 |
| Brendel, BS | 1 |
| Slichter, SJ | 1 |
| Hackel, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| A Pilot Study Examining the Value of Combined Exercise and Adenosine Stress Myocardial Perfusion Imaging as Compared With Adenosine Testing Alone for the Evaluation of Women at Intermediate or High Likelihood for Coronary Artery Disease[NCT00200629] | Phase 4 | 200 participants (Anticipated) | Interventional | 2005-06-30 | Terminated (stopped due to Poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
15 reviews available for dipyridamole and Vascular Diseases
| Article | Year |
|---|---|
Semiquantitative dipyridamole myocardial stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a meta-analysis.
Topics: Dipyridamole; Exercise Test; Heart; Humans; Intraoperative Complications; Myocardial Infarction; Pos | 2002 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease.
Topics: Death, Sudden, Cardiac; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction; Plat | 2003 |
A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery.
Topics: Cardiotonic Agents; Dipyridamole; Dopamine; Echocardiography, Stress; Electrocardiography, Ambulator | 2003 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Vascular complications of Fabry disease: enzyme replacement and other therapies.
Topics: alpha-Galactosidase; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Blood Coagulati | 2005 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
The role of dipyridamole in the therapy of vascular disease.
Topics: Animals; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Survival; Heart Valve Prosthesis; Huma | 1993 |
Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery.
Topics: Adrenergic beta-Agonists; Aged; Dipyridamole; Dobutamine; Echocardiography; Exercise Test; Female; H | 1996 |
Prostaglandins in circulatory disorders.
Topics: Angiotensin II; Antihypertensive Agents; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platele | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
8 trials available for dipyridamole and Vascular Diseases
| Article | Year |
|---|---|
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
Doubts about dipyridamole as an antithrombotic drug.
Topics: Antithrombins; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial | 1984 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
Plasma factor and platelet sensitivity to prostacyclin in patients with peripheral vascular disease before and after treatment with a combination of a cyclooxygenase and a phosphodiesterase inhibitor.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dipyridamole; Drug Th | 1984 |
Noninvasive detection of cardiac graft vascular disease.
Topics: Dipyridamole; Dobutamine; Echocardiography; Exercise Test; Female; Follow-Up Studies; Graft Rejectio | 1995 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
25 other studies available for dipyridamole and Vascular Diseases
| Article | Year |
|---|---|
Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.
Topics: Adolescent; Adult; Aspirin; Dipyridamole; Female; Fibrinolysis; Humans; Male; Plasminogen Activator | 2011 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90).
Topics: Aspirin; Clopidogrel; Constriction, Pathologic; Delayed-Action Preparations; Dipyridamole; Drugs, Ge | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Antiplatelet drugs.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dextrans; Dipyridamole; Epopr | 1983 |
Model system to study interaction of platelets with damaged arterial wall. I. Inhibition of platelet adhesion to subendothelium by aspirin and dipyridamole.
Topics: Animals; Arteries; Aspirin; Dipyridamole; Endothelium; Heparin; Male; Microscopy, Electron; Platelet | 1984 |
Non-surgical management of peripheral vascular disease.
Topics: Aspirin; Dipyridamole; Female; Humans; Male; Vascular Diseases | 1981 |
Studies on platelet aggregation and antiplatelet therapy in blackfoot disease.
Topics: Adult; Aged; Aspirin; Dipyridamole; Female; Foot Diseases; Gangrene; Humans; Male; Middle Aged; Plat | 1981 |
[Present situation of therapy with platelet aggregation inhibitors].
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Middle Aged; | 1982 |
Sex differences in perioperative and long-term cardiac event-free survival in vascular surgery patients. An analysis of clinical and scintigraphic variables.
Topics: Aged; Cohort Studies; Death, Sudden, Cardiac; Dipyridamole; Disease-Free Survival; Female; Heart; Hu | 1995 |
Cardiac risk stratification using dipyridamole myocardial perfusion imaging and ambulatory ECG monitoring prior to vascular surgery.
Topics: Adult; Aged; Cause of Death; Coronary Circulation; Death, Sudden, Cardiac; Dipyridamole; Electrocard | 1993 |
Usefulness of dipyridamole-thallium imaging in 257 patients with atherosclerotic vascular disease.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Aortic Dissection; A | 1995 |
Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates.
Topics: Aged; Bayes Theorem; Cohort Studies; Dipyridamole; Female; Heart Diseases; Humans; Logistic Models; | 1996 |
Cardiac risk for vascular surgery.
Topics: Adrenergic beta-Agonists; Bayes Theorem; Decision Making; Dipyridamole; Dobutamine; Echocardiography | 1996 |
The predictive value of dipyridamole-thallium scintigraphy for cardiac risk assessment before major vascular surgery.
Topics: Aged; Aortic Aneurysm, Abdominal; Arterial Occlusive Diseases; Coronary Disease; Dipyridamole; Femal | 1998 |
Preoperative cardiac evaluation is unnecessary in most patients undergoing vascular operations.
Topics: Aged; Dipyridamole; Humans; Male; Patient Selection; Predictive Value of Tests; Preoperative Care; R | 1998 |
The effect of dipyridamole on peritoneal mass transport.
Topics: Animals; Creatinine; Dipyridamole; Humans; Kidney; Kidney Failure, Chronic; Metabolic Clearance Rate | 1977 |
Dipyridamole-thallium scintigraphy predicts perioperative and long-term survival after major vascular surgery.
Topics: Aged; Dipyridamole; Female; Heart Diseases; Humans; Life Tables; Male; Middle Aged; Postoperative Co | 1992 |
Dipyridamole echocardiography stress testing in hypertensive patients. Targets and tools.
Topics: Cardiomegaly; Coronary Disease; Dipyridamole; Echocardiography; Exercise; Humans; Hypertension; Micr | 1991 |
Perioperative and long-term prognostic value of intravenous dipyridamole thallium scintigraphy in patients with peripheral vascular disease.
Topics: Aged; Angiography; Coronary Angiography; Dipyridamole; Female; Follow-Up Studies; Humans; Injections | 1990 |
[Chronic treatment of vascular diseases with indobufen].
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Isoindoles; Middle Aged; Phen | 1989 |
Prevention of cardiac complications in peripheral vascular surgery.
Topics: Angiography; Arrhythmias, Cardiac; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Electr | 1986 |
The effect of heparin and dipyridamole on chronic vascular lesions in monkey cardiac allografts.
Topics: Animals; Azathioprine; Dipyridamole; Female; Haplorhini; Heart Transplantation; Heparin; Macaca; Mal | 1972 |
[Cardiovascular complications in operated patients more than 70 years old suffering from cardiovascular insufficiency].
Topics: Age Factors; Aged; Aminophylline; Anesthesia, General; Aspartic Acid; Cardiac Surgical Procedures; D | 1972 |
Platelet and fibrinogen consumption in man.
Topics: Blood Cell Count; Blood Platelets; Catheterization; Cell Survival; Dipyridamole; Disseminated Intrav | 1972 |
[Importance of dipyridamole (Curantyl) in the pharmacotherapy of peripheral arterial blood circulation disorders].
Topics: Blood Circulation; Dipyridamole; Glomerular Filtration Rate; Humans; Kidney; Leg; Vascular Diseases | 1971 |